Long-Term Cannabis Therapy May Change MS Spasticity Outcomes
Cannabis for MS spasticity was associated with meaningful symptom improvement in a new meta-analysis involving 2,544 multiple sclerosis patients across nine trials. The strongest benefits emerged with longer treatment duration, while short-term effects…
Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.
A new consensus from Italian neurologists proposes enhancing the endocannabinoid system multiple sclerosis treatment approach for patients with relapse-free disease. The algorithm combines cannabinoid agents with lifestyle interventions to address…
Persistent and debilitating muscle spasms | Center for Medical Cannabis – Utah.gov
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic SpasticityClinical GuidelinesMultiple…
Over 70% of MS patients in rehab take 5 or more medications, study finds
✦ New CED Clinical Relevance #80High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic Multiple…
Honoring the trailblazers with MS who changed cannabis policy – Blog
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Multiple SclerosisSpasticityMedical…
MS cases double in England over 20 years; life expectancy rises
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Multiple SclerosisSpasticityChronic…
Investigating the effectiveness and adverse events of medicinal cannabis for patients with muscle spasticity or spasms.
Appropriate treatment of muscle spasticity and spasms is important as these conditions may significantly impair patients' quality of life. Conventional pharm...
Cannabis for MS Spasticity: A Systematic Review With Critically Unreliable Pooled Estimates
Substantial heterogeneity (I² = 100% for overall and AS analyses; 91% for NRS) and asymmetry in funnel plots suggest possible publication bias and study variability.
Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.
The recent introduction of High-Efficacy Therapies (HETs) in clinical practice has drastically reduced the frequency of acute inflammatory episodes and relap...